A Four Part Study to Investigate Relative Bioavailability, Safety and Tolerability of up to 5 Oral Formulation of GSK2251052 in Order to Identify a Formulation for Further Evaluation in a Future Later Phase Study

PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 21, 2011

Primary Completion Date

December 8, 2011

Study Completion Date

December 8, 2011

Conditions

Community-acquired Infection

Interventions

DRUG

GSK2251052

Oral formulation of an an antibacterial

Trial Locations (1)

GSK Investigational Site, Adelaide